These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24369276)

  • 21. Safety of bisphosphonates.
    Orozco C; Maalouf NM
    Rheum Dis Clin North Am; 2012 Nov; 38(4):681-705. PubMed ID: 23137577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive approach to fragility fractures.
    Rebolledo BJ; Unnanuntana A; Lane JM
    J Orthop Trauma; 2011 Sep; 25(9):566-73. PubMed ID: 21654529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duration of anti-resorptive therapy for osteoporosis.
    Adler RA
    Endocrine; 2016 Feb; 51(2):222-4. PubMed ID: 26433739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment thresholds for osteoporosis and reimbursability criteria: perspectives associated with fracture risk-assessment tools.
    Adami S; Bertoldo F; Gatti D; Minisola G; Rossini M; Sinigaglia L; Varenna M
    Calcif Tissue Int; 2013 Sep; 93(3):195-200. PubMed ID: 23754490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis: an update.
    Honig S; Chang G
    Bull NYU Hosp Jt Dis; 2012; 70(3):140-4. PubMed ID: 23259620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?
    Yoon RS; Hwang JS; Beebe KS
    J Bone Joint Surg Br; 2011 Oct; 93(10):1289-95. PubMed ID: 21969423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for osteoporosis.
    Croswell J
    Am Fam Physician; 2011 May; 83(10):1201-2. PubMed ID: 21568255
    [No Abstract]   [Full Text] [Related]  

  • 28. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NSAIDs and opioids in management of fragility fractures.
    Iolascon G; Cisari C; Moretti A; Frizzi L; Gimigliano R; Gimigliano F
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S97-100. PubMed ID: 24046027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteoporosis in men: update 2011.
    Orwig DL; Chiles N; Jones M; Hochberg MC
    Rheum Dis Clin North Am; 2011 Aug; 37(3):401-14, vi. PubMed ID: 22023899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.
    Perreault S; Dragomir A; Blais L; Moride Y; Rossignol M; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):248-59. PubMed ID: 18213734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updated approach for the management of osteoporosis in Turkey: a consensus report.
    Kirazlı Y; Atamaz Çalış F; El Ö; Gökçe Kutsal Y; Peker Ö; Sindel D; Tuzun Ş; Gogas Yavuz D; Durmaz B; Akarirmak Ü; Bodur H; Hamuryudan V; Inceboz U; Öncel S
    Arch Osteoporos; 2020 Aug; 15(1):137. PubMed ID: 32860546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 39. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 40. Screening for osteoporosis: recommendation statement.
    U.S. Preventive Services Task Force
    Am Fam Physician; 2011 May; 83(10):1197-200. PubMed ID: 21568254
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.